Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Pharmacometric and statistical considerations for dose optimization

Chotsiri P. et al, (2024), CPT: Pharmacometrics & Systems Pharmacology

Population pharmacokinetic modelling of primaquine exposures in lactating women and breastfed infants

Wattanakul T. et al, (2024), Nature Communications, 15

Medication adherence framework: A population‐based pharmacokinetic approach and its application in antimalarial treatment assessments

Ding J. et al, (2024), CPT: Pharmacometrics & Systems Pharmacology

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study

Flower B. et al, (2023), eLife, 12

Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers

Chotsiri P. et al, (2022), Clinical Pharmacology & Therapeutics, 112, 824 - 835

A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics.

Wattanakul T. et al, (2022), Expert Rev Clin Pharmacol

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

Assmus F. et al, (2022), Microorganisms, 10, 1639 - 1639

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

Driouich J-S. et al, (2022), eBioMedicine, 82, 104148 - 104148

Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Peto TJ. et al, (2022), The Lancet Infectious Diseases, 22, 867 - 878

Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside

Assmus F. et al, (2022), PLOS Neglected Tropical Diseases, 16, e0010219 - e0010219

Mechanistic Modeling of Primaquine Pharmacokinetics, Gametocytocidal Activity, and Mosquito Infectivity

Chotsiri P. et al, (2022), Clinical Pharmacology & Therapeutics, 111, 676 - 685

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

Abdelnabi R. et al, (2022), Nature Communications, 13

Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria

Taylor WR. et al, (2021), Malaria Journal, 20

Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence".

Ding J. et al, (2021), Clinical pharmacology and therapeutics, 110, 24 - 25

Development of Weight and Age-based Dosing of Daily Primaquine for Radical Cure of Vivax Malaria

Taylor WR. et al, (2021)

Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa

Fanello C. et al, (2021), Antimicrobial Agents and Chemotherapy, 65

Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria

Wattanakul T. et al, (2021), Antimicrobial Agents and Chemotherapy, 65

Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis

Panjasawatwong N. et al, (2020), Antimicrobial Agents and Chemotherapy, 65

COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology

White NJ. et al, (2020), PLOS Medicine, 17, e1003252 - e1003252

Concentration-dependent mortality of chloroquine in overdose

Watson JA. et al, (2020), eLife, 9

Load More

Include forthcoming?